IN8Bio Reports Q2 2026 Financial Results with $4.8 Million Net Loss

IN8Bio, Inc. has reported its financial results for the second quarter of 2026, revealing a net loss of $4.8 million, a slight improvement from the $5.1 million loss recorded in the same period last year. For the six months ending June 30, 2026, the company reported a net loss of $9.9 million, compared to a loss of $10.6 million for the first half of 2025. The company’s total operating expenses for the second quarter were $4.9 million, down from $5.2 million in the prior year, primarily due to a reduction in general and administrative costs.

The company’s cash position has decreased significantly, with cash and restricted cash totaling $18.1 million as of June 30, 2026, down from $27.3 million at the end of 2025. This decline is attributed to ongoing operational losses and cash used in operating activities, which amounted to $8.7 million for the first half of 2026. IN8Bio has not yet generated any revenue from product sales, as it continues to focus on the development of its gamma-delta T cell therapies for cancer and autoimmune diseases.

Operationally, IN8Bio is advancing its clinical programs, including the ongoing Phase 1 trials for its lead product candidates, INB-100 and INB-200. The company has also introduced INB-600, a new T cell engager platform, and expects to report initial in vivo data for INB-619 in the second half of 2026. The company is actively pursuing strategic collaborations and additional funding to support its clinical development efforts, as it anticipates that its current cash reserves will not sustain operations beyond April 2027.

In terms of organizational changes, IN8Bio has implemented cash preservation measures to manage its financial resources more effectively. The company is exploring various avenues for raising capital, including equity and debt offerings, as well as potential collaborations to support the development of its product candidates. The company’s management has expressed concerns regarding its ability to continue as a going concern if additional funding is not secured in a timely manner.

Looking ahead, IN8Bio remains focused on advancing its clinical trials and achieving key milestones in its product development pipeline. The company is also preparing for potential regulatory submissions and commercialization efforts, contingent on the successful outcomes of its ongoing trials. However, the company acknowledges that its ability to execute its strategy may be impacted by market conditions and the need for additional capital.